The global Atrophic Vaginitis Treatment Market had a market value of US$ 2.57 billion in 2022 and is predicted to reach a market value of US$ 6 billion by 2023, growing at an 8% CAGR from 2023 to 2033. The increasing prevalence of the ailment, the rising elderly population, and the growing awareness of the importance of women’s health all contribute to the growth of the atrophic vaginitis treatment market. From 2018 to 2022, the market for atrophic vaginitis treatment grew at a CAGR of 4.1%.
The atrophic vaginitis treatment market is expected to grow significantly in the coming years due to the increasing prevalence of the condition. According to a report published by the National Institutes of Health, approximately 50% of women experience vaginal dryness and discomfort after menopause, and around 10-40% of these women experience atrophic vaginitis. This translates to millions of women who are in need of proper treatment.
The market offers various treatment options, including hormone replacement therapy, topical estrogen creams, and vaginal moisturizers. Hormone replacement therapy is one of the most effective treatments for atrophic vaginitis. It involves taking hormones to replace the estrogen that the body is no longer producing. This treatment has been proven to reduce symptoms such as vaginal dryness, itching, and painful intercourse.
Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16831
Topical estrogen creams are another popular treatment option. These creams are applied directly to the vagina and help to restore the natural moisture and elasticity of the vaginal tissues. They are easy to use and have been shown to be effective in relieving symptoms. Thus, with the availability of effective treatments, the atrophic vaginitis market is expected to grow in the upcoming years.
Key Takeaways from the Market Study
- The global Atrophic vaginitis treatment market is expected to grow with an 8% CAGR during 2023 to 2033.
- By therapy type, Estrogen based therapy are expected to hold 53% of the market share in 2023 for Atrophic vaginitis treatment market.
- North America is expected to possess 48% market share for Atrophic vaginitis treatment market in 2023.
- Europe Atrophic vaginitis treatment market size is expected to possess 43% market share in 2023.
“The atrophic vaginitis treatment market is revolutionizing women’s health by providing effective solutions to a common condition that affects millions of women worldwide. With the increasing prevalence of the condition, the market is expected to grow significantly in the coming years. Despite the challenges faced by the industry” states an FMI analyst
Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16831
Hormone Replacement Therapy for Vaginal Atrophy is a condition that can cause vaginal dryness, itching, and discomfort. It occurs when the tissues of the vagina become thin and dry due to a decrease in estrogen levels, which can happen during menopause or as a side effect of certain medications or medical conditions.
Competitive Landscape
- Shionogi is a pharmaceutical company that has developed a treatment for atrophic vaginitis called Intrarosa (prasterone). Intrarosa is a vaginal insert that contains the hormone dehydroepiandrosterone (DHEA), which is converted into estrogen in the body.
- Bayer HealthCare Pharmaceuticals Inc, a key player in the atrophic vaginitis treatment market is focusing on developing treatments for the ailment by researching and investing in developing therapies.
Key Companies Profiled:
- Shionogi
- Duchesnay
- Hormos Medical
- QuatRx Pharmaceuticals
- Pantarhei Bioscience
- Mithra Pharmaceuticals
- AMAG Pharmaceuticals
- Bayer HealthCare Pharmaceuticals Inc
- Theramex
- Endoceutics, Inc.
Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/16831
Key Segments Profiled in the Atrophic Vaginitis Treatment Industry Survey
Diagnosis:
- Pelvic exam
- Urine test
- Acid balance test
Treatment:
- Vaginal moisturizers
- Water-based lubricants
Therapy Type:
- Estrogen based drugs
- Non-estrogen based drugs
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
